Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium.

Winde Jorissen Lieven Annemans Nicolas Louis Andreas Nilsson Michael Willis

Published in: Acta clinica Belgica (2021)

Model-based results suggest that adding canagliflozin 100 mg to SoC can improve outcomes for patients with DKD while reducing overall net costs for the Belgian healthcare system.

Keyphrases

public health
healthcare
type diabetes
mental health
health information
wound healing
health promotion
metabolic syndrome
skeletal muscle
adipose tissue
risk assessment
insulin resistance
climate change